Natural Capsules Limited · NSE:NATCAPSUQ
Natural Capsules — Q4 FY2022 Earnings Presentation
35 slides from Natural Capsules's earnings presentation, May 9, 2022
Slide 1: Cover letter to BSE: Investor Presentation
NATURAL 7, _ ce Ae CAPSULES & aunty Jeroen ee CREDITED — tHe wa e G caps ww LIMITED 7 See ~CORP& REGD OFFICE ‘ TRIDENT TOWERS® No. 23, 4th Floor, 100 feet car and Block, Bangalore-56001| ~T:on Phone : O80- 26561562 Road, Jayanagar 2ndCINBloc 742 080-2e656 / 1871/15 73 ‘S81 U RI Www naturalcapsules.c
Slide 2: Investor Presentation FY 2022
naturalcapsules.com investor Presentation AY, 2022
Slide 3: Safe Harbor
Safe Harbor PRESENTATION Certain statements and opinions with respect to the anticipated future performance of Natural Capsules Limited (NCL) in the presentation (“forward - looking statements”), which reflect various assumptions concerning the INVESTOR strategies, objectives and anticipated results
Slide 4: Inside this document
Inside this document PRESENTATION INVESTOR OVERVIEW CANVAS Q Lu FINANCIAL INVESTMENT QUARTERLY Kk = PERFORMANCE MERITS HIGHLIGHTS a 7) Lu —! a) 7) oO oi O —! oi [a a) Kk oi a
Slide 5: Company Overview
naturalcapsules.com Company Overview
Slide 6: Introducing Natural Capsules Limited (NCL)
Introducing Natural Capsules Limited (NCL) PRESENTATION Natural Capsules Limited (NCL) is a hard capsule shell manufacturer, who pioneered manufacturing of vegetarian capsules in India and is the second largest Indian manufacturer for gelatin capsules. The company was incorporated as a Public Limite
Slide 7: Our Journey
Our Journey PRESENTATION 1993- 2014: EARLY SUCCESSES AND A PERIOD OF EXPANSION INVESTOR e NCL was ° Soon after, in ° 2003 was an ° The coming * In 2005-2007, NCL ° In 2009-2012, ¢ In 2012-14, NCL incorporated in 2001, NCL important decade witnessed acquired 5 lines NCL acquired upgraded 3 more 1993,
Slide 8: Our Journey 2015-2018 and Going Forward
2015 —- 2018: THE HURDLES WE GOING FORWARD FACED ON THE WAY By Q2FY22, four new generation machines were Fall in oil and commodity prices led to economic 2019 onward NCL witnessed an increase in slowdown in African countries and caused a demand in both domestic and export markets, commissioned, whic
Slide 9: Product Offerings
Product Offerings PRESENTATION Natural Capsules Limited manufactures a vast array INVESTOR capsules, including vegetarian capsules which they have pioneered in India. The company in now foraying into API manufacturing with complex CAPSULES APIs high-end patented technology developed in-house, under
Slide 10: Global Presence
Global Presence PRESENTATION Natural Capsules exports to 37 countries across 4 continents, bringing in AFRICA Algeria MIDDLE EAST ASIA sizable revenue from Its export. Mozambique ° lrag Ivory Coast Kuwait INVESTOR Ghana Syria Kenya Iran % OF TOTAL SALES Nigeria United Arab Emirates South Africa Suda
Slide 11: Serving Leading Brands
Serving Leading Brands PRESENTATION With over 3 decades of experience in the pharma sector, NCL has garnered CUSTOMERS FOR MORE THAN excellent relationship with customers across 37 countries. The company Is now 10 YEARS focused on acquiring customers who deal with regulated markets. INVESTOR LW sto5
Slide 12: Leadership Team
Leadership Team PRESENTATION INVESTOR X Mr. Laxminarayan Mundra Mr. Satyanarayana Mundra Mr. Sushil Kumar Mundra Mr. Sunil Mundra WHOLE TIME DIRECTOR WHOLE TIME DIRECTOR DIRECTOR MANAGING DIRECTOR Q Lu Kk = a 7) Lu —! a) 7) oO oi O —! oi Mr. Pramod Kasat Mr. C P Rangachar Mr. Anjan Kumar Roy Mrs. Jy
Slide 13: Business Canvas
naturalcapsules.com Business Canvas
Slide 14: Capsules Segment
Capsules Segment PRESENTATION With almost three decades of experience in the industry, Natural Capsules Limited is a leading manufacturer of hard capsules in India, its products are exported to regulated and unregulated markets across the globe, 2nd largest INVESTOR following stringent applicable ru
Slide 15: Enhancing Capacities
Enhancing Capacities PRESENTATION Natural Capsules Limited has undergone recent CAPEX, to support its existing manufacturing capacity and to enable the company to capture market share in regulated markets. INVESTOR CAPSULES MANUFACTURING CAPACITY The ability to deliver faster = 38 Crores planned cap
Slide 16: API Segment
API Segment PRESENTATION Natural Capsules Limited is now foraying into the API business segment through its wholly owned subsidiary - Natural Biogenex Private Limited Greenfield Capex at (NBPL) incorporated in 2020. The APIs that will be manufactured are, Tumkur, spread across INVESTOR 5 acres Predn
Slide 17: API Segment (contd.)
API Seg ment (contd.) Ss a3 THE FOLLOWING PRODUCTS AND CAPACITIES HAVE BEEN APPROVED UNDER THE PLI SCHEME ” INR 96 Crores - planned capital o expenditure for setting up the DEXAMETHASONE 5 facility 7 10 MT 19 MT ° NCL will be the only = Planned Capacity Imports to India in FY21 manufacturer Soa ~ 3x
Slide 18: Production Linked Incentive (PLI) Scheme
The scheme intends to boost domestic manufacturing { of identified KSMs, Drug Intermediates and APIs by attracting large investments in the sector and thereby reduce India’s import dependence in critical APIs. With a view to attain self-reliance and reduce import A committee on drug security constit
Slide 19: Focus on R&D
Focus on R&D PRESENTATION NCL strongly believes in investing in R&D, to stay ahead of its peers and to consistently innovate. The Company's recent entry into the API business is 2 DSIR a testament to its firm belief in R&D. Recognised state of the INVESTOR art R&D facilities R&D SPENDS & KEY AREAS O
Slide 20: naturalcapsules.c
a naturalcapsules.c ah}
Slide 21: Sustainability
Sustainability PRESENTATION Initiatives Zero discharge facilities Solar power generation INVESTOR SUSTAINABLE SITES Solar concentrated heat generation funded by IREDA and 1st company to receive UNIDO grant for patented solar concentrated heat generation dishes in India _—_— NCL believes in Recycling
Slide 22: Financial Performance
naturalcapsules.com * a ¢ wy He Bic lcet) Darfr = ee ~ 7s
Slide 23: Profit & Loss Statement Summary
Profit & Loss Statement Summary PRESENTATION PARTICULARS (IN cRoRES) FY18 FY19 FY20 FY21 FY22 INVESTOR Revenue from Operations 54.76 59.78 61.55 79.51 135.07 Other Income 0.81 1.13 0.95 0.73 1.01 Total Income 55.57 60.91 62.50 80.24 136.10 Total Operating Expenses 49.35 54.89 56.25 68.58 109.69 EBIT
Slide 24: Balance Sheet Summary
Balance Sheet Summary PRESENTATION PARTICULARS (z IN CRORES) FY18 FY19 FY20 FY21 FY22 INVESTOR Total Equity (Networth) 54.32 55.49 55.62 62.10 82.98 Non Current Liabilities 2.17 1.23 1.08 1.55 34.85 Current Liabilities 14.56 17.61 17.98 33.30 46.45 Total Equity and Liability 71.05 74.33 74.68 97.05
Slide 25: Cash Flow Statement Summary
Cash Flow Statement Summary PARTICULARS (IN cRoRES) FY18 FY19 FY20 FY21 2 Cash Flow from Operating Activities 5.34 2.09 6.90 5.78 1.16 Cash Flow from Investing Activities (0.93) (7.06) (5.74) (8.54) (45.88) Cash Flow from Financing Activities (3.92) 4.28 (1.18) 2.52 46.02 Net increase/ (decrease) in
Slide 26: Investment Merits
naturalcapsules.com investment Merits
Slide 27: Growth Drivers
Growth Drivers PRESENTATION {1 Ip LL Al INVESTOR Capacity enhancement with Being the only backward Exploring opportunities The Company will benefit state-of-the-art machinery integrated manufacturer to set up capsules from strong industry tailwinds in capsules division, enabling of steroidal APIs in
Slide 28: Strategic Priorities
Strategic Priorities PRESENTATION NCL ts geared to bring about monumental changes in its approach towards its business. & ce INVESTOR With the ongoing CAPEX, the STRATEGIC PRIORITY ACTIONS TAKEN Company Is enabling itself to Positioning the business to reduce margin Collaborating with buyers who pro
Slide 29: Quarterly Highlights
naturalcapsules.com Quarterly Highlights
Slide 30: Quarterly Updates
Quarterly Updates REVENUES EBITDA ® 10.48% ® 6.13% ® 79.71% ® 131.25% EBITDA MARGINS PAT © 80 BPS ® 24.88% @ 437 BPS ® 214.11% EPS KEY ® 20.00% @ 20-QGromt ) Y-o-Y Growth @ 179.68%
Slide 31: Management Commentary
Management Commentary PRESENTATION “It gives me immense pleasure to report that we have had a strong Q4FY22, with volumetric growth of 7.5% and realisation growth of 2.5%. The installation of one line at the beginning of March 2022 INVESTOR aided in increasing our volumes this quarter. Given the dem
Slide 32: CAPEX Tracker
CAPEX Tracker PRESENTATION Natural Capsules is geared to make significant capital expenditures in the quarters to come and is on track with its capsule business. The Company will focus on ramping up Its endeavours in its API business in the coming quarters. INVESTOR OCS 74 oul a 7x) Q2FY23 Q3FY23 Q4
Slide 33: Profit & Loss Statement Summary (Consolidated)
Profit & Loss Statement Summary (Consolidated) PRESENTATION PARTICULARS (2 IN CRORES) Q4FY21 Q3FY22 eC 774 FY21 FY22 INVESTOR Revenue from Operations 23.12 37.61 41.55 79.51 135.07 Other Income 0.20 0.06 0.81 0.73 1.01 Total Income 23.32 37.67 42.36 80.24 136.10 Total Operating Expenses 19.60 29.94
Slide 34: Balance Sheet Summary (Consolidated)
Balance Sheet Summa [Y (Consolidated) PRESENTATION PARTICULARS (z IN CRORES) FY21 a ar INVESTOR Total Equity (Networth) 62.10 82.98 Non Current Liabilities 1.55 34.85 Current Liabilities 33.30 46.45 Total Equity and Liability 97.05 164.28 Non Current Assets 47.35 88.70 Q Lu Kk = a Current Assets 49.
Slide 35: Thank You
tS Pil NATURAL naturalcapsules.com CAPSULES 6318 Limitep Thank You CONTACT US FOR FURTHER INFORMATION, PLEASE CONTACT Natural Capsules Limited Mrs. Shilpa Burman Mr. Abhishek Mehra TRIDENT TOWERS, COMPANY SECRETARY INVESTOR RELATIONS ADVISOR Fourth Floor, No. 23, +91 95588 14500 100 Feet Road, Jayna